5,116 results on '"Basiliximab"'
Search Results
152. Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
- Author
-
Astellas Pharma Canada, Inc.
- Published
- 2019
153. Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (TRANSFORM)
- Published
- 2019
154. Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
- Author
-
National Center for Kidney Diseases and Surgery and Sarra Elamin, Consultant Physician and Nephrologist
- Published
- 2019
155. Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study.
- Author
-
Wu Y, Sun G, Tang B, Song K, Cheng Y, Tu M, and Zhu X
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Adolescent, Young Adult, Child, Steroids therapeutic use, Child, Preschool, Acute Disease, Immunosuppressive Agents therapeutic use, Treatment Outcome, Drug Therapy, Combination, Graft vs Host Disease drug therapy, Pyrazoles therapeutic use, Nitriles therapeutic use, Basiliximab therapeutic use, Pyrimidines therapeutic use, Cord Blood Stem Cell Transplantation
- Abstract
Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation. We aimed to evaluate the effectiveness and safety of ruxolitinib plus basiliximab for treating SR-aGVHD after unrelated cord blood transplantation (UCBT). Among the 1154 patients with hematological malignancies who underwent UCBT between February 2014 and May 2022, 198 patients with grade II to IV SR-aGVHD were enrolled, 112 of whom were treated with basiliximab alone (basiliximab group) and 86 of whom received basiliximab plus ruxolitinib (combined therapy group). The combined therapy group demonstrated a significantly higher complete response rate (CRR) on day 28 (36.0%) than did the basiliximab group (12.5%, P < .001). SR-aGVHD patients were further stratified into standard-risk and high-risk groups using the refined Minnesota aGVHD risk score. For standard-risk patients, combined therapy significantly improved the CRR (51.1% versus 13.6%, P < .001) and 3-year overall survival (74.5% versus 52.4%, P = .033). However, high-risk patients did not exhibit the same benefits. Compared with basiliximab monotherapy, ruxolitinib plus basiliximab therapy was an effective therapy for patients with standard-risk SR-aGVHD following UCBT. The effectiveness of combined therapy in high-risk patients was not apparent, indicating the need for other treatments., (Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
156. The impact of induction therapy on the risk of posttransplant lymphoproliferative disorder in adult kidney transplant recipients with donor-recipient serological Epstein-Barr virus mismatch.
- Author
-
Attieh RM, Wadei HM, Mao MA, Mao SA, Pungpapong S, Taner CB, Jarmi T, Cheungpasitporn W, and Leeaphorn N
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Risk Factors, Follow-Up Studies, Prognosis, Antilymphocyte Serum adverse effects, Retrospective Studies, Kidney Failure, Chronic surgery, Transplant Recipients, Incidence, Induction Chemotherapy adverse effects, Basiliximab, Alemtuzumab adverse effects, Kidney Function Tests, Kidney Transplantation adverse effects, Lymphoproliferative Disorders etiology, Epstein-Barr Virus Infections complications, Epstein-Barr Virus Infections etiology, Epstein-Barr Virus Infections virology, Herpesvirus 4, Human, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Tissue Donors, Graft Survival, Graft Rejection etiology, Postoperative Complications
- Abstract
Posttransplant lymphoproliferative disorder (PTLD) poses a significant concern in Epstein-Barr virus (EBV)-negative patients transplanted from EBV-positive donors (EBV R-/D+). Previous studies investigating the association between different induction agents and PTLD in these patients have yielded conflicting results. Using the Organ Procurement and Transplant Network database, we identified EBV R-/D+ patients >18 years of age who underwent kidney-alone transplants between 2016 and 2022 and compared the risk of PTLD with rabbit antithymocyte globulin (ATG), basiliximab, and alemtuzumab inductions. Among the 6620 patients included, 64.0% received ATG, 23.4% received basiliximab, and 12.6% received alemtuzumab. The overall incidence of PTLD was 2.5% over a median follow-up period of 2.9 years. Multivariable analysis demonstrated that the risk of PTLD was significantly higher with ATG and alemtuzumab compared with basiliximab (adjusted subdistribution hazard ratio [aSHR] = 1.98, 95% confidence interval [CI] 1.29-3.04, P = .002 for ATG and aSHR = 1.80, 95% CI 1.04-3.11, P = .04 for alemtuzumab). However, PTLD risk was comparable between ATG and alemtuzumab inductions (aSHR = 1.13, 95% CI 0.72-1.77, P = .61). Therefore, the risk of PTLD must be taken into consideration when selecting the most appropriate induction therapy for this patient population., (Copyright © 2024 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
157. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
- Author
-
Gao Z, Fan Z, Liu Z, Ye X, Zeng Y, Xuan L, Huang F, Lin R, Sun J, Liu Q, and Xu N
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Young Adult, Adolescent, Drug Therapy, Combination, Treatment Outcome, Gastrointestinal Diseases etiology, Drug Resistance, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Acute Disease, Steroids therapeutic use, Aged, Retrospective Studies, Graft vs Host Disease drug therapy, Graft vs Host Disease etiology, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Basiliximab therapeutic use, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Background: Steroid-resistant (SR) lower gastrointestinal (LGI) tract graft-versus-host disease (GVHD) is the predominant cause of morbidity and mortality from GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The role of vedolizumab in the treatment of SR-LGI acute GVHD (aGVHD) remains uncertain. We aimed to assess the efficacy and safety of vedolizumab combined with basiliximab as second-line therapy for SR-LGI-aGVHD., Methods: This study aimed to explore the efficacy of vedolizumab combined with basiliximab for SR-LGI-aGVHD. The primary endpoint was the overall response (OR) on day 28. Secondary and safety endpoints included durable OR at day 56, overall survival (OS), chronic GVHD (cGVHD), non-relapse mortality (NRM), failure-free survival (FFS), and adverse events., Results: Twenty-eight patients with SR-LGI-aGVHD were included. The median time to start of combination therapy after SR-LGI-aGVHD diagnosis was 7 (range, 4-16) days. The overall response rate (ORR) at 28 days was 75.0% (95% CI: 54.8%-88.6%), and 18 achieved a complete response (CR) (64.3%, 95% CI: 44.1%-80.7%). The durable OR at day 56 was 64.3% (95% CI: 44.1%-80.7%). The 100-day, 6-month, and 12-month OS rates for the entire cohort of patients were 60.7% (95% CI: 45.1%-81.8%), 60.7% (95% CI: 45.1%-81.8%), and 47.6% (95% CI: 31.4%-72.1%), respectively. The median failure-free survival was 276 days; (95% CI: 50-not evaluable) 12-month NRM was 42.9% (95% CI: 24.1%-60.3%). The 1-year cumulative incidence of cGVHD was 35.7%. Within 180 days after study treatments, the most common grade 3 and 4 adverse events were infections. Nine (32.1%) patients developed cytomegalovirus (CMV) reactivation complicated with bacterial infections (25.0%, CMV infection; 7.1%, CMV viremia). Epstein-Barr virus (EBV) reactivation occurred in five patients (17.9%, 95% CI: 6.8%-37.6%). Only three patients (10.7%, 95% CI: 2.8%-29.4%) in our study developed pseudomembranous colitis., Conclusions: Vedolizumab plus basiliximab demonstrated efficacy in severe SR-LGI-aGVHD and was well-tolerated. Vedolizumab plus basiliximab may be considered a potential treatment option for patients with LGI-aGVHD., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Gao, Fan, Liu, Ye, Zeng, Xuan, Huang, Lin, Sun, Liu and Xu.)
- Published
- 2024
- Full Text
- View/download PDF
158. Findings in Cell Transplants Reported from Chinese Academy of Medical Sciences (Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation)
- Subjects
Medical research ,Medicine, Experimental ,Basiliximab ,Stem cells ,Diseases -- Care and treatment -- China ,Hematopoietic stem cells -- Transplantation ,Biological sciences ,Health - Abstract
2024 JUN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators discuss new findings in cell transplants. According to news reporting from Beijing, People's [...]
- Published
- 2024
159. Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report
- Author
-
Tingting Chen, Xiaoyu Li, Jina Wang, Xuanchuan Wang, Tongyu Zhu, Ruiming Rong, and Cheng Yang
- Subjects
basiliximab ,acute T cell–mediated rejection ,BK virus ,kidney ,transplantation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
A 66-year-old Chinese man underwent a deceased donor kidney transplantation. Induction-immunosuppressive protocol consisted of basiliximab (BAS) and methyl prednisolone (MP), followed by maintenance immunosuppression with cyclosporin (CsA), mycophenolate mofetil (MMF), and prednisone (PED). The patient’s post-transplantation course was almost uneventful, and the graft was functioning well [serum creatinine (Scr) 2.15 mg/dL]. The MMF and CsA doses were decreased 1-month post-operative as the BK virus activation was serologically positive. His Scr was elevated to 2.45 mg/dL 45 days after the transplant. A graft biopsy showed BKV nephropathy (BKVN) and acute T cell–mediated rejection (TCMR) Banff grade IIA (I2, t2, ptc2, v1, c4d1, g0, and SV40 positive). The conventional anti-rejection therapy could deteriorate his BKVN, therefore, we administered BAS to eliminate activated graft-infiltrating T cells and combined with low-dose steroid. He responded well to the therapy after two doses of BAS were given, and the kidney graft status has been stable (recent Scr 2.1 mg/dL).
- Published
- 2022
- Full Text
- View/download PDF
160. 33600000-6 Pharmaceutical Products (simulect (basiliximab); Tigacil (tigecycline); Thymoglobulin (antithymocyte Immunoglobulin (rabbit)); Heptral (ademetionine); Korvitin (comb Drug)
- Subjects
Basiliximab ,Immunoglobulins ,S-adenosylmethionine ,Business, international - Abstract
Tenders are invited for:33600000-6 pharmaceutical products (simulect (basiliximab); tigacil (tigecycline); thymoglobulin (antithymocyte immunoglobulin (rabbit)); heptral (ademetionine); corvityn (comb drug). 33600000-6 pharmaceutical products (simulect (basiliximab); tigacil (tigecycline); thymoglobulin (antithymocyte immunoglobulin (rabbit)); [...]
- Published
- 2024
161. Provision Of Drugs-basiliximab
- Subjects
Basiliximab ,Business, international - Abstract
Tenders are invited for Drugs-Basiliximab Estimated value: 2.255.882,00 Deadline for submission: 12.03.2024 09:00:00 Address: University Childrens Clinic, Tirova 10, Belgrade. Tender notice number: 2024/ 02-0005416 Notice type: Tender Notice Open [...]
- Published
- 2024
162. National Classifier Of Ukraine Unified Procurement Dictionary Dk 021:2015: 33600000-6 - Pharmaceutical Products (simulect (basiliximab))
- Subjects
Purchasing ,Basiliximab ,Business, international - Abstract
Tenders are invited for: national classifier of ukraine unified procurement dictionary dk 021:2015: 33600000-6 - pharmaceutical products (simulect (basiliximab)) National classifier of ukraine unified procurement dictionary dk 021:2015: 33600000-6 - [...]
- Published
- 2024
163. Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form.
- Author
-
Tiankanon, Kanitha, Kerr, Stephen J., Thongthip, Siriwan, Udomkarnjananun, Suwasin, Sodsai, Pimpayao, Vorasittha, Athaya, Panumatrassamee, Kamol, Takkavatakarn, Kullaya, Tungsanga, Kriang, Eiam-Ong, Somchai, Praditpornsilpa, Kearkiat, Avihingsanon, Yingyos, and Townamchai, Natavudh
- Subjects
- *
BASILIXIMAB , *CYTOCHROME P-450 CYP3A , *TACROLIMUS , *MYCOPHENOLIC acid , *KIDNEY transplantation - Abstract
Twice daily TAC (BID TAC) and prolonged released once daily dose tacrolimus (OD TAC) have different pharmacokinetic (PK) profiles in kidney transplant (KT) recipients. Precise dose adjustment recommendations when converting from BID TAC to OD TAC remain inconclusive. A single center, PK study was conducted in stable KT recipients taking constant doses of TAC, mycophenolic acid, and prednisolone. The area under the concentration–time curve (AUC) 0–24 and Ctrough were measured before and 4 weeks after 1:1 conversion from BID TAC to OD TAC without subsequent dose adjustment. A 90% confidence interval (CI) of geometric mean ratio (GMR) of OD TAC/BID TAC within the range of 0.9–1.11 was utilized to indicate equivalence of the narrow therapeutic index drugs. The roles of CYP3A5 genotypic polymorphism on PK parameters were also assessed. There were 20 patients with median time since transplantation of 18 months. The mean of CKD-EPI eGFR was 60.7 ± 16.43 mL/min/1.73 m2. The median total daily TAC dose of 0.058 mg/kg/day. The geometric means (%CV) of AUC0-24 of OD and BID TAC were 205.16 (36.4%) and 210.3 (32.5%) ng/mL × h, respectively, with a GMR of 0.98 (90%CI 0.91–1.04). The geometric means (%CV) of Ctrough of OD TAC and BID TAC were 5.43 (33.1%) and 6.09 (34.6%) ng/mL, respectively. The GMR of Ctrough was 0.89 (90%CI 0.82–0.98), which was below 0.9. The newly calculated target Ctrough level of OD TAC was 4.8–6.2 ng/mL. The best abbreviated AUC0-24 was AUC = 0.97(C0) + 5.79(C6) + 18.97(C12) − 4.26. The GMR AUC0-24 was within the range of 0.9–1.11 irrespective of CYP3A5 genotypic polymorphism while the GMR of Ctrough was below 0.9 only in the CYP3A5 expressor patients. The 1:1 conversion from BID TAC to OD TAC without subsequent dose adjustment provided similar AUC0-24 regardless of CYP3A5 genotypic polymorphism. However, the Ctrough was lower in the CYP3A5 expressor group. Therefore, it is not necessary to routinely increase the OD TAC dose after conversion. Trial registration: Thai Clinical Trials Registry (TCTR20210715002). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
164. Therapeutic Drug Monitoring of Mycophenolic Acid as a Precision Medicine Tool for Heart Transplant Patients: Results of an Observational Pharmacokinetic Pilot Study.
- Author
-
Lo Re, Francesco, Angelini, Jacopo, Sponga, Sandro, Nalli, Chiara, Zucchetto, Antonella, Biasizzo, Jessica, Livi, Ugolino, and Baraldo, Massimo
- Subjects
- *
DRUG monitoring , *HEART transplant recipients , *MYCOPHENOLIC acid , *INDIVIDUALIZED medicine , *PHARMACOKINETICS , *BELATACEPT , *BASILIXIMAB - Abstract
In the clinical practice management of heart transplant (HTx), the impact of calcineurin inhibitors co-administration on pharmacokinetics (PKs) of mycophenolic acid (MPA), mycophenolate mofetil (MMF) active drug, is not adequately considered. This retrospective study investigated full MPA-PK profiles by therapeutic drug monitoring (TDM) in 21 HTx recipients treated with MMF combined with cyclosporine (CsA) or tacrolimus (TAC) at a median time of 2.6 months post-transplant. The two treatment groups were compared. We described the main MPA-PK parameters in patients developing acute cellular rejection (ACR) and those who did not. Median dose-adjusted MPA-trough levels and MPA-AUC0–12h were higher in patients co-treated with TAC than with CsA (p = 0.0001 and p = 0.006, respectively). MPA-Cmax and Tmax were similar between the two groups, whereas the enterohepatic recirculation biomarker of MPA (MPA-AUC4–12h) was higher in the MMF and TAC group (p = 0.004). Consistently, MPA clearance was higher in the MMF and CsA group (p = 0.006). In total, 87.5% of ACR patients were treated with MMF and CsA, presenting a lower MPA-AUC0–12h (p = 0.02). This real-world study suggested the CsA interference on MPA-PK in HTx, evidencing the pivotal role of MPA TDM as a precision medicine tool in the early phase after HTx. A prospective study is mandatory to investigate this approach to HTx clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
165. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy in Heart Transplantation: New Strategies and Preliminary Results in Endomyocardial Biopsies.
- Author
-
De Gregori, Simona, De Silvestri, Annalisa, Cattadori, Barbara, Rapagnani, Andrea, Albertini, Riccardo, Novello, Elisa, Concardi, Monica, Arbustini, Eloisa, and Pellegrini, Carlo
- Subjects
- *
DRUG monitoring , *HEART transplantation , *BASILIXIMAB , *BIOPSY - Abstract
Tacrolimus (TAC) is an immunosuppressant drug approved both in the US and in the EU, widely used for the prophylaxis of organ rejection after transplantation. This is a critical dose drug: low levels in whole blood can lead to low exposure and a high risk of acute rejection, whereas overexposure puts patients at risk for toxicity and infection. Both situations can occur at whole-blood concentrations considered to be within the narrow TAC therapeutic range. We assumed a poor correlation between TAC trough concentrations in whole blood and the incidence of acute rejection; therefore, we propose to study TAC concentrations in endomyocardial biopsies (EMBs). We analyzed 70 EMBs from 18 transplant recipients at five scheduled follow-up visits during the first year post-transplant when closer TAC monitoring is mandatory. We observed five episodes of acute rejection (grade 2R) in three patients (2 episodes at 0.5 months, 2 at 3 months, and 1 at 12 months), when TAC concentrations in EMBs were low (63; 62; 59; 31; 44 pg/mg, respectively), whereas concentrations in whole blood were correct. Our results are preliminary and further studies are needed to confirm the importance of this new strategy to prevent acute rejection episodes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
166. Evaluation of a batched-extraction method for measurement of sirolimus, tacrolimus, and cyclosporine on the Architect i2000SR.
- Author
-
Di Meo, Ashley, Youkhana, Sandra, Khalifeh, Seham, and Brinc, Davor
- Subjects
- *
RAPAMYCIN , *CYCLOSPORINE , *DRUG monitoring , *OVERUSE injuries , *BASILIXIMAB , *TACROLIMUS , *EVALUATION methodology - Abstract
• Therapeutic drug monitoring (TDM) of immunosuppressants in whole blood plays an important role in the management of transplant recipients. • Semiautomated sirolimus, tacrolimus, and cyclosporine immunoassays require offline extraction that places clinical laboratory staff at increased risk of repetitive strain injury. • Implementation of batched extraction methods following internal validation can help to reduce repetitive strain injury associated with offline extraction. • Batched and individual extraction methods for sirolimus, tacrolimus, and cyclosporine showed good agreement. Manual extraction of immunosuppressants is required before measurement on the Architect immunoassay analyzer. The individual extraction of samples places clinical laboratory staff at risk for ergonomic injury. We evaluated the analytical performance of a batched extraction method for measuring sirolimus, tacrolimus, and cyclosporine using the Architect i2000SR. Residual whole blood samples from patients receiving immunosuppressant therapy were used for evaluation. The analytical evaluation included imprecision, linearity, and method comparison. Technologist-to-technologist variation was also assessed. Total imprecision ranged from 2.58 to 3.13% for sirolimus, 2.70–3.77% for tacrolimus, and 7.82–12.41% for cyclosporine. Linearity was verified from 0.44–19.49 μg/l for sirolimus, 0.05–26.15 μg/l for tacrolimus, and 0.15–991.55 μg/l for cyclosporine. Deming regression analysis showed slope and intercept were not significant for either technologist-to-technologist comparison or for batched vs. individual processing comparison. Bland-Altman analysis of individual vs. batched processing revealed a mean bias of 1.29% (LLOA: −14.63%, ULOA: 17.21%) for sirolimus, 2.07% (LLOA: −10.87%, ULOA: 15%) for tacrolimus, and −1.56% (LLOA: −20.05%, ULOA: 16.94%) for cyclosporine. The values were not significantly different from the bias and LLOAs observed for technologist-to-technologist comparison. The imprecision and linearity of batched methods met analytical goals. The batched method also correlated well with the individual extraction methods. The ULOA and LLOA for all drugs tested exceeded a TAE or ± 15%. However, similar range of differences was observed between technologists, suggesting that batch processing did not increase or reduce variability due to manual preparation steps. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
167. Influence of cytotoxic T lymphocyte antigen 4 genetic variants on acute rejection in kidney transplant patients: precision medicine perspective.
- Author
-
Taleb, Andia, Afshari, Mahdi, Samzadeh, Mohammad, Sarhangi, Negar, Nafar, Mohsen, and Hasanzad, Mandana
- Subjects
- *
CYTOTOXIC T cells , *KIDNEY transplantation , *INDIVIDUALIZED medicine , *GENETIC variation , *GRAFT rejection , *BASILIXIMAB , *T cells , *CHRONIC kidney failure - Abstract
Background: The most effective and common treatment for end-stage renal disease is kidney transplantation. The personalized approach to kidney transplantation, which utilizes precision medicine principles, determines distinctive genomics characteristics of candidates/recipients that must be taken into account. Cytotoxic T lymphocyte associated protein 4 (CTLA4) may be a suitable candidate gene for studying allograft rejection. The aim of this study was to understand whether we can consider two common variants of the CTLA4 gene as a risk factor of transplant rejection in a group of Iranian population. Methods: Totally, 169 kidney transplant recipients, including acute rejections (N=39) and non-rejection (N=130) groups who underwent transplantation were included in this study. The genotyping of rs5742909 (−318C/T) and rs231775 (+49A/G) variants of the CTLA4 gene were performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Results: The AG genotype frequency of rs231775 variant was the same in both patients with and without a history of rejection while, none of those groups had homozygote genotype. In rs5742909, both CT and TT frequencies of patients with rejected transplant were lower than patients with a normal outcome. Conclusions: The results of the presented study suggest that rs231775 and rs5742909 of CTLA4 genetic variants are not linked to acute rejection who underwent kidney transplantation. So, these variants cannot be considered as risk factors of acute allograft rejection in a group of Iranian renal transplantation recipients. However, the transplantation precision medicine may be an important area for the improvement of patients outcome as the precision medicine has already entered clinical practice in kidney transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
168. Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience.
- Author
-
Furukawa, Masashi, Chan, Ernest G., Ryan, John P., Hyzny, Eric J., Sacha, Lauren M., Coster, Jenalee N., Pilewski, Joseph M., Lendermon, Elizabeth A., Kilaru, Silpa D., McDyer, John F., and Sanchez, Pablo G.
- Subjects
KIDNEY transplantation ,BASILIXIMAB ,TRANSPLANTATION of organs, tissues, etc. ,ALEMTUZUMAB ,LUNG transplantation ,HIV infections ,GRAFT rejection - Abstract
Background: Induction therapy is used in about 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guidelines for the use of induction therapy. At our institution, we have two induction strategies, basiliximab, and alemtuzumab. The goal of this manuscript is to share our experience and practice since this is an area of controversy. Methods: We retrospectively reviewed 807 lung transplants performed at our institution between 2011 and 2020. Indications for the use of the basiliximab protocol were as follows: patients over the age of 70 years, history of cancer, hepatitis C virus or human immunodeficiency virus infection history, and cytomegalovirus or Epstein-Barr virus (donor positive/ recipient negative). In the absence of these clinical factors, the alemtuzumab protocol was used. Results: 453 patients underwent alemtuzumab induction and 354 patients underwent basiliximab. There were significant differences in delayed chest closure (24.7% alemtuzumab vs 31.4% basiliximab, p = 0.037), grade 3 primary graft dysfunction observed within 72 hours (19.9% alemtuzumab vs 29.9% basiliximab, p = 0.002), postoperative hepatic dysfunction (8.8% alemtuzumab vs 14.7% basiliximab, p = 0.009), acute cellular rejection in first year (39.1% alemtuzumab vs 53.4% basiliximab, p < 0.001). The overall survival rate of the patients with alemtuzumab induction was significantly higher than those of the patients with basiliximab induction (5 years survival rate: 64.1% alemtuzumab vs 52.3%, basiliximab, p < 0.001). Multivariate Cox regression analysis confirmed lower 5-year survival for basiliximab induction (HR = 1.41, p = 0.02), recipient cytomegalovirus positive (HR = 1.49, p = 0.01), postoperative hepatic dysfunction (HR = 2.20, p < 0.001), and acute kidney injury requiring renal replacement therapy (HR = 2.27, p < 0.001). Conclusions: In this single center retrospective review, there was a significant difference in survival rates between induction strategies. This outcome may be attributable to differences in recipient characteristics between the groups. However, the Alemtuzumab group experienced less episodes of acute cellular rejection within the first year. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
169. Clinical Characteristics of Transplant Recipients Infected with Talaromyces Marneffei: 2 Case Reports and a Literature Review.
- Author
-
Xing, Suke, Zhang, Hui, Qiu, Ye, Pan, Mianluan, Zeng, Wen, and Zhang, Jianquan
- Subjects
COUGH ,BONE marrow transplantation ,ALEMTUZUMAB ,BASILIXIMAB ,TALAROMYCES ,LUNG transplantation ,AMPHOTERICIN B - Abstract
Purpose: To summarize the clinical characteristics, treatment and outcomes of transplant recipients infected with Talaromyces marneffei (TM). Materials and Methods: A retrospective analysis was performed on 2 patients with Talaromycosis marneffei (TSM) and transplants at the First Affiliated Hospital of Guangxi Medical University, and a systematic literature review was conducted simultaneously. Results: This article reported two patients after kidney transplantation who developed fever, cough within 3– 4 months. Their haemoglobin was decreased. Their chest computed tomography (CT) showed nodules. TM was detected in their blood or bronchoalveolar lavage fluid samples by next-generation sequencing (NGS). After antifungal treatment with voriconazole (VOR), one patient worsened, the other patient died. A total of 21 patients with TSM after transplants were reported in the literature review. Fourteen underwent kidney transplantation, 4 underwent liver transplantation, 2 underwent lung transplantation, and 1 underwent bone marrow transplantation. The median time from initiating the postoperative immunosuppressive therapy to the onset of symptoms or disease changes was 18 (0.5– 140) months. Among them, 9 patients developed fever, 7 patients developed cough or expectoration and 4 patients developed dyspnoea. Haemoglobin was decreased in 10 patients. Pulmonary nodules were found in 7 patients. Among the 21 patients, 7 were diagnosed by positive culture, 6 by biopsy, 5 by culture and biopsy. Of the 21 patients, 13 patients improved by antifungal therapy, 8 patients worsened or died. Seven patients who received amphotericin B followed by itraconazole (ITR) therapy all improved. Regarding the use of immunosuppressants in 12 patients, 9 patients had to discontinue or reduce their medications (6 patients improved, 3 patients worsened or died). Conclusion: Patients with TSM after transplant often have disseminated infections, involving the respiratory, hematopoietic and so on. Fever, cough, decreased haemoglobin and pulmonary nodules often occur approximately 18 months after surgery. The combined applications of culture, biopsy, NGS are helpful for an early diagnosis. Antifungal therapy with amphotericin B followed by itraconazole is recommended, and the dosage of the immunosuppressant should be adjusted timely. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
170. The Potential Association of Delayed T Lymphocyte Reconstitution Within Six Months Post-Transplantation With the Risk of Cytomegalovirus Retinitis in Severe Aplastic Anemia Recipients.
- Author
-
Mo, Wenjian, Chen, Xiangting, Zhang, Xu, Wang, Shunqing, Li, Ling, and Zhang, Yuehong
- Subjects
T cells ,APLASTIC anemia ,KILLER cells ,BASILIXIMAB ,LYMPHOCYTE subsets ,HEMATOPOIETIC stem cell transplantation - Abstract
Background: Delayed immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT) is significantly associated with cytomegalovirus (CMV) infection. The aim of this study was to observe the recovery trend of peripheral lymphocyte subsets and immunoglobulins in HSCT recipients who developed CMV retinitis (CMVR). Methods: We identified 37 CMVR cases and 303 non-CMVR controls in this case-control study from a database of 404 consecutive severe aplastic anemia patients who received allogeneic HSCT at a single center between 2015 and 2020. We analyzed the transplant outcomes and immune reconstitution principles with a focus on lymphocyte CD series and immunoglobulin series within the first year post-HSCT. Results: Thirty-seven patients (55 eyes) were diagnosed with CMVR, with a mean onset time of 155 days post-HSCT. Among the 37 patients, one never had CMV detected in his blood but had a high CMV load in his intraocular fluid at the time of CMVR diagnosis. In the controls, 195 had CMV viremia and 108 did not. Compared with controls, CMVR cases had a longer duration of CMV viremia and a higher peak number of CMV load. T lymphocyte subsets including CD3, CD4 and CD8 were significantly lower in CMVR cases within six months after HSCT (all p < 0.05). Immunoglobulins also showed a slower recovery trend in CMVR cases. The recovery of B lymphocytes and natural killer cells exhibited no significant differences between the two groups. Conclusions: It is not enough to develop fundus screening strategies by merely relying on the CMV serostatus of recipients. Dynamic and continuous monitoring of T lymphocyte subsets, especially within six months post-HSCT, as well as serum immunoglobulin levels, can provide assistance with screening program of CMVR in HSCT recipients with severe aplastic anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
171. Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages.
- Author
-
Wang, Peile, Xie, Hongchang, Zhang, Qiwen, Tian, Xueke, Feng, Yi, Qin, Zifei, Yang, Jing, Shang, Wenjun, Feng, Guiwen, and Zhang, Xiaojian
- Subjects
MYCOPHENOLIC acid ,KIDNEY transplantation ,DRUG monitoring ,MONTE Carlo method ,PHARMACOKINETICS ,BASILIXIMAB - Abstract
Mycophenolic acid (MPA) is an antimetabolic immunosuppressive drug widely used in solid organ transplantation and autoimmune diseases. Pharmacokinetics (PK) of MPA demonstrates high inter- and intra-variability. The aim of this study was to compare the population PK properties of MPA in adult renal transplant patients in the early and stable post-transplant stages and to simulate an optimal dosing regimen for patients at different stages. A total of 51 patients in the early post-transplant period (1 week after surgery) and 48 patients in the stable state (5.5–10 years after surgery) were included in the study. In the two-compartment population PK model, CL/F (23.36 L/h vs. 10.25 L/h) and V/F (78.07 vs. 16.24 L) were significantly different between the two stages. The dose-adjusted area under the concentration time curve (AUC
ss,12h /dose) for patients in the early stage were significantly lower than those for patients in the stable state (40.83 ± 22.26 mg h/L vs. 77.86 ± 21.34 mg h/L; p < 0.001). According to Monte Carlo simulations, patients with 1.0–1.5 g of mycophenolate mofetil twice daily in the early phase and 0.50–0.75 g twice daily in the stable phase had a high probability of achieving an AUCss,12h of 30–60 mg h/L. In addition, limited sampling strategies showed that two 4-point models (C0-C1-C2-C4 and C1-C2-C3-C6) performed well in predicting MPA exposure by both Bayesian estimate and regression equation and could be applied in clinical practice to assist therapeutic drug monitoring of MPA. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
172. Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4.
- Author
-
Hang, Zhou, Wei, Jintao, Zheng, Ming, Gui, Zeping, Chen, Hao, Sun, Li, Fei, Shuang, Han, Zhijian, Tao, Jun, Wang, Zijie, Tan, Ruoyun, and Gu, Min
- Subjects
KIDNEY transplantation ,GRAFT rejection ,SKIN grafting ,MACROPHAGES ,MESSENGER RNA ,BASILIXIMAB - Abstract
Background: This study aimed to explore the effect and mechanism of iguratimod (IGT) on M1 macrophage polarization and antibody-mediated rejection (ABMR) after renal transplant. Methods: Bioinformatics analysis was performed using three public databases derived from the GEO database. Sprague–Dawley (SD) rats were pre-sensitized with donors of Wistar rats in skin transplantation and a rat renal transplant ABMR model was established from the donors to skin pre-sensitized recipients. Subsequently, IGT was treated on the ABMR model. Routine staining and immunofluorescence (IF) staining were performed to observe the pathological changes in each group and flow cytometry was performed to detect the changes of DSA titers in peripheral blood. In addition, bone-marrow-derived macrophage (BMDM) was extracted and interfered with IGT to explore the effect of IGT in vivo. PCR, IF staining, and Western blot were used to detect the expression of related genes and proteins. Results: Bioinformatics analysis revealed that several immune cells were significantly infiltrated in the ABMR allograft, while M1 macrophage was noticed with the most significance. Results of IF staining and PCR proved the findings of the bioinformatics analysis. Based on this, IGT was observed to significantly attenuate the degree of peritubular capillary vasculitis and arteriolitis in the rat renal transplant ABMR model, whereas it decreases the expression of C4d and reduces the titer of DSA. Results in vitro suggested that M1 macrophage-related transcripts and proteins were significantly reduced by the treatment of IGT in a dose- and time-dependent manner. Furthermore, IGT intervention could remarkably decrease the expression of KLF4. Conclusion: Polarization of M1 macrophages may aggravate ABMR after renal transplant by promoting DSA-mediated endothelial cell injury, and IGT may attenuate the pathogenesis of ABMR by targeting KLF4. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
173. Oral and Poster Presentations.
- Subjects
- *
BASILIXIMAB , *POSTER presentations , *MONOCLONAL antibodies , *KILLER cells , *HLA histocompatibility antigens , *APPLIED sciences , *IMMUNOLOGIC memory , *CELL analysis - Abstract
To test this, we used the hierarchical PBM clustering of 122 HLA class I allotypes (44 HLA-A, 63 HLA-B, and 18 HLA-C) to identify 21 distinct PBM groups. O14 The pre-transplant non-HLA antibody burden predicts the development of histology of antibody-... Aleksandar Senev 1, Bryan Ray 2, Jayasree Hariharan 2, Christine Heylen 2, Marie-Paule Em... 1 KU Leuven, Belgium, 2 Immucor Inc, United States B Correspondence: b aleksenev@yahoo.com In this study we aimed to investigate the role of 82 different non-HLA antibodies in the occurrence of histology of ABMR after kidney transplantation. We developed an assay that estimated the binding strength of HLA II-peptide interaction by measuring the cell-surface expression of HLA II-peptide fusion construct. In the present study, we used a newly developed HLA II-peptide interaction assay to identify HLA II-binding regions in SARS-CoV-2 Spike and the mutations that might affect the interaction with HLA II. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
174. Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients.
- Author
-
McCune, Jeannine S., Nakamura, Ryotaro, O'Meally, Denis, Randolph, Timothy W., Sandmaier, Brenda M., Karolak, Aleksandra, Hockenbery, David, and Navarro, Sandi L.
- Subjects
- *
BUSULFAN , *BASILIXIMAB , *HEMATOPOIETIC stem cell transplantation , *FLUDARABINE , *FALSE discovery rate , *ALKYLATING agents , *CYCLOPHOSPHAMIDE , *EXPORT trading companies - Abstract
The widely used alkylating agent cyclophosphamide (CY) has substantive interpatient variability in the area under the curve (AUC) of it and its metabolites. Numerous factors may influence the drug‐metabolizing enzymes that metabolize CY to 4‐hydroxycyclophosphamide (4HCY), the principal precursor to CY's cytotoxic metabolite. We sought to identify endogenous metabolomics compounds (EMCs) associated with 4HCY formation clearance (ratio of 4HCY/CY AUC) using global metabolomics. Patients who undergo hematopoietic cell transplantation receiving post‐transplant CY (PT‐CY) were enrolled, cohort 1 (n = 26) and cohort 2 (n = 25) donating longitudinal blood samples before they started HCT (pre‐HCT), before infusion of the donor allograft (pre‐graft), before the first dose of PT‐CY (pre‐CY), and 24 h after the first dose of PT‐CY (24‐h post‐CY), which is also immediately before the second dose of CY. A total of 512 and 498 EMCs were quantitated in two cohorts, respectively. Both univariate linear regression with false discovery rate (FDR), and pathway enrichment analyses using a global association test were performed. At the pre‐CY time point, no EMCs were associated at FDR less than 0.1. At pre‐HCT, cohort 1 had one EMC (levoglucosan) survive the FDR threshold. At pre‐graft, cohort 1 and cohort 2 had 20 and 13 EMCs, respectively, exhibiting unadjusted p values less than 0.05, with the only EMCs having an FDR less than 0.1 being two unknown EMCs. At 24‐h post‐CY, there were three EMCs, two ketones, and threitol, at FDR less than 0.1 in cohort 2. These results demonstrate the potential of pharmacometabonomics, but future studies in larger samples are needed to optimize CY. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
175. CXCL10 and Soluble Programmed Death-Ligand 1 during Respiratory Viral Infections Are Associated with Chronic Lung Allograft Dysfunction in Lung Transplant Recipients.
- Author
-
Morrell, Eric D., Brager, Carolyn, Ramos, Kathleen J., Xin-Ya Chai, Kapnadak, Siddhartha G., Edelman, Jeffrey, Matute-Bello, Gustavo, Altemeier, William A., Hwang, Billanna, Mulligan, Michael S., Bhatraju, Pavan K., Wurfel, Mark M., Mikacenic, Carmen, Lease, Erika D., Limaye, Ajit P., and Fisher, Cynthia E.
- Subjects
PROGRAMMED death-ligand 1 ,CHEMOKINES ,LUNG transplantation ,VIRUS diseases ,RESPIRATORY infections ,PROGRAMMED cell death 1 receptors ,BASILIXIMAB ,IMMUNOASSAY - Published
- 2022
- Full Text
- View/download PDF
176. Kidney Stones, Proteinuria and Renal Tubular Metabolic Acidosis: What Is the Link?
- Author
-
Ilzkovitz, Maxime, Kayembe, Elikyah Esther, Geers, Caroline, and Pozdzik, Agnieszka
- Subjects
KIDNEY stones ,ACIDOSIS ,SJOGREN'S syndrome ,PROTEINURIA ,CHRONIC kidney failure ,BASILIXIMAB - Abstract
Kidney stone disease represents a rare cause of chronic kidney disease (2–3%) but has severe clinical consequences. Type 1 renal tubular acidosis is a strong lithogenic condition mainly related to primary Sjögren syndrome. This study aimed to illustrate an unusual presentation of Sjögren syndrome to improve the knowledge about rare kidney stone diseases, and to provide clues for the diagnostic approach in this specific condition. We report the case of a 35-year-old Indian woman with severe nephrocalcinosis and chronic kidney disease with tubular proteinuria who presented for metabolic assessment. We found advanced chronic kidney disease, low serum bicarbonate, permanent alkaline urine with pH at ~7.1, and severe hypocitraturia corresponding to type 1 renal tubular acidosis. The erythrocyte sedimentation rate was high. Serological screening for HAV, HBV, HCV, HIV, EBV was negative and complement was normal. Autoimmune screening showed antinuclear antibodies (>1/1.280) with anti-SSA, anti-SSA/Ro52 and anti-SSB antibodies. Genetic testing excluded an inherited cause of renal tubular acidosis. A renal biopsy showed moderate chronic tubulo-interstitial nephritis without any glomerular involvement. Primary Sjögren syndrome with significant renal involvement was considered, and corticosteroids were then subsequently initiated in combination with potassium citrate with vitamin D substitution. Only partial improvement was observed in electrolytes disturbance. After 15 months, her renal function remained stable. In conclusion, nephrocalcinosis could be the first manifestation of severely impacting diseases such as primary Sjögren syndrome. Chronic kidney disease, bilateral nephrocalcinosis, and metabolic acidosis can be linked through type 1 renal tubular acidosis. Therefore, autoimmune screening for Sjögren syndrome should be considered in such cases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
177. Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients.
- Author
-
Tu, Zhen-Hua, Jin, Ping-Bo, Chen, Di-Yu, Chen, Zhi-Yun, Li, Zhi-Wei, Wu, Jie, Lou, Bin, Zhang, Bao-Shan, Zhang, Lin, Zhang, Wei, and Liang, Ting-Bo
- Subjects
VACCINATION complications ,LIVER transplantation ,COVID-19 vaccines ,COVID-19 ,BOOSTER vaccines ,BASILIXIMAB ,IMMUNOGLOBULINS ,LIVER - Abstract
Purpose: To evaluate the response and safety of an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) for coronavirus disease 2019 (COVID-19) in liver transplant (LTx) recipients from China. Patients and Methods: Thirty-five recipients post LTx from the First Affiliated Hospital of Zhejiang University School of Medicine who received inactivated vaccine from June to October 2021 were screened. Information regarding vaccine side effects and clinical data were collected. Results: Thirty-five LTx recipients were enrolled, with a mean age of 46 years, and most patients were male (30, 85.71%). All the participants had a negative history of COVID-19 infection. Predictors for negative response in the recipients were interleukin-2 receptor (IL-2R) induction during LTx, shorter time post LTx and application of a derivative from mycophenolate acid (MPA). No serious adverse events were observed during the progress of vaccination or after the vaccination. Conclusion: LTx recipients have a substantially partial immunological response to the inactivated vaccine for COVID-19. IL-2R induction during LTx, a shorter time post LTx and the application of a derivative from MPA seem to be predictors for a negative serological immunoglobulin G (IgG) antibody response in recipients. The findings require booster vaccination in these LTx recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
178. Antibody response to double SARS-CoV-2 mRNA vaccination in Japanese kidney transplant recipients.
- Author
-
Fujieda, Kumiko, Tanaka, Akihito, Kikuchi, Ryosuke, Takai, Nami, Saito, Shoji, Yasuda, Yoshinari, Fujita, Takashi, Kato, Masashi, Furuhashi, Kazuhiro, and Maruyama, Shoichi
- Subjects
- *
ANTIBODY formation , *KIDNEY transplantation , *VACCINATION complications , *IMMUNOGLOBULINS , *SARS-CoV-2 , *VACCINATION , *TACROLIMUS , *BASILIXIMAB - Abstract
Immunocompromised patients, especially those who undergo kidney transplantation, have lower antibody levels following SARS-CoV-2 mRNA vaccination. The situation of transplant treatment, such as transplant source and immunosuppressive drugs, is different in Japan than that in other countries. Therefore, it is necessary to clarify whether antibody acquisition rates differ between Japan and other countries. This retrospective study included patients with post-kidney transplant who were attending at the Nagoya University Hospital. The anti-SARS-CoV-2 IgG antibody titers were measured between 3 weeks and 3 months after vaccination. Seventy-three patients (45 men and 28 women) were included. Of these, 23 (31.5%) showed antibody presence, and the rates of antibody acquisition were very low than those in the control group (100.0% vs. 31.5%, P < 0.05). Antibody acquisition rates were associated with body mass index (odds ratio [OR]: 1.21, 95% confidence interval [CI]: 1.04–1.39, P < 0.05) and the duration between transplantation and vaccination (OR: 1.01, 95% CI: 1.00–1.02, P < 0.05). The immunosuppressive drugs used were: prednisolone in all cases, tacrolimus in 89.0%, cyclosporine in 9.6%, and mofetil mycophenolate in 97.3%. None of the patients were excluded from receiving two doses of the vaccine due to adverse effects. The study indicated that vaccination-induced antibody acquisition rates against SARS-CoV-2 were extremely low in Japanese patients who underwent post-kidney transplantation. Thus, despite two doses of vaccination, it is necessary to closely monitor infection control in such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
179. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
- Author
-
Hamaya, Tomoko, Hatakeyama, Shingo, Yoneyama, Tohru, Tobisawa, Yuki, Kodama, Hirotake, Fujita, Takeshi, Murakami, Reiichi, Fujita, Naoki, Okamoto, Teppei, Yamamoto, Hayato, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Saitoh, Hisao, Narumi, Shunji, Tomita, Hirofumi, and Ohyama, Chikara
- Subjects
- *
KIDNEY transplantation , *COVID-19 vaccines , *ABO blood group system , *IMMUNOGLOBULIN G , *RITUXIMAB , *MESSENGER RNA , *BASILIXIMAB - Abstract
We aimed to evaluate the seroprevalence and investigated factors associated with seropositivity after the second SARS-CoV-2 mRNA vaccination in kidney transplant (KT) recipients. This retrospective study conducted between June and November 2021 included 106 KT recipients and 127 healthy controls who received the second dose of the BNT162b2 mRNA vaccine at least 7 days before the measurement of antibody titers. The antibody titer against the receptor-binding domain of SARS-CoV-2 spike (S) protein was determined. We compared seroprevalence rates (immunoglobulin G [IgG] level of ≥ 0.8 or ≥ 15 U/mL) between the healthy controls and KT recipients and identified factors associated with impaired humoral response. The seroprevalence rate of the healthy controls and KT recipients was 98% and 22%, respectively. Univariate logistic regression analysis revealed that age > 53 years, rituximab use, mycophenolate mofetil use, and KT vintage < 7 years were negatively associated with the rate of anti-SARS-CoV-2 S IgG ≥ 15 U/mL in KT recipients. ABO blood type incompatible KT was not significantly associated with seroprevalence. Humoral response after the second BNT162b2 mRNA vaccine was greatly hindered by immunosuppression therapy in KT recipients. Older age, rituximab use, mycophenolate mofetil use, and KT vintage may play key roles in seroconversion. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
180. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
- Author
-
Mayer, Katharina A., Budde, Klemens, Halloran, Philip F., Doberer, Konstantin, Rostaing, Lionel, Eskandary, Farsad, Christamentl, Anna, Wahrmann, Markus, Regele, Heinz, Schranz, Sabine, Ely, Sarah, Firbas, Christa, Schörgenhofer, Christian, Kainz, Alexander, Loupy, Alexandre, Härtle, Stefan, Boxhammer, Rainer, Jilma, Bernd, and Böhmig, Georg A.
- Subjects
- *
GRAFT rejection , *MONOCLONAL antibodies , *KILLER cells , *PLASMA cells , *RESEARCH protocols , *BASILIXIMAB , *IMMUNOGLOBULINS - Abstract
Background: Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after transplantation, commonly presents as a continuum of microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical relevance of ABMR is well recognized, its treatment, particularly a long time after transplantation, has remained a big challenge. A promising strategy to counteract ABMR may be the use of CD38-directed treatment to deplete alloantibody-producing plasma cells (PC) and natural killer (NK) cells.Methods: This investigator-initiated trial is planned as a randomized, placebo-controlled, double-blind, parallel-group, multi-center phase 2 trial designed to assess the safety and tolerability (primary endpoint), pharmacokinetics, immunogenicity, and efficacy of the fully human CD38 monoclonal antibody felzartamab (MOR202) in late ABMR. The trial will include 20 anti-HLA donor-specific antibody (DSA)-positive renal allograft recipients diagnosed with active or chronic active ABMR ≥ 180 days post-transplantation. Subjects will be randomized 1:1 to receive felzartamab (16 mg/kg per infusion) or placebo for a period of 6 months (intravenous administration on day 0, and after 1, 2, 3, 4, 8, 12, 16, and 20 weeks). Two follow-up allograft biopsies will be performed at weeks 24 and 52. Secondary endpoints (preliminary assessment) will include morphologic and molecular rejection activity in renal biopsies, immunologic biomarkers in the blood and urine, and surrogate parameters predicting the progression to allograft failure (slope of renal function; iBOX prediction score).Discussion: Based on the hypothesis that felzartamab is able to halt the progression of ABMR via targeting antibody-producing PC and NK cells, we believe that our trial could potentially provide the first proof of concept of a new treatment in ABMR based on a prospective randomized clinical trial.Trial Registration: EU Clinical Trials Register (EudraCT) 2021-000545-40 . Registered on 23 June 2021.Clinicaltrials: gov NCT05021484 . Registered on 25 August 2021. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
181. Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients.
- Author
-
Kirubakaran, Ranita, Hennig, Stefanie, Maslen, Ben, Day, Richard O., Carland, Jane E., and Stocker, Sophie L.
- Subjects
- *
TACROLIMUS , *HEART transplant recipients , *BASILIXIMAB , *PHARMACOKINETICS , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Background and Aim: Identification of the most appropriate population pharmacokinetic model‐based Bayesian estimation is required prior to its implementation in routine clinical practice to inform tacrolimus dosing decisions. This study aimed to determine the predictive performances of relevant population pharmacokinetic models of tacrolimus developed from various solid organ transplant recipient populations in adult heart transplant recipients, stratified based on concomitant azole antifungal use. Concomitant azole antifungal therapy alters tacrolimus pharmacokinetics substantially, necessitating dose adjustments. Methods: Population pharmacokinetic models of tacrolimus were selected (n = 17) for evaluation from a recent systematic review. The models were transcribed and implemented in NONMEM version 7.4.3. Data from 85 heart transplant recipients (2387 tacrolimus concentrations) administered the oral immediate‐release formulation of tacrolimus (Prograf) were obtained up to 391 days post‐transplant. The performance of each model was evaluated using: (i) prediction‐based assessment (bias and imprecision) of the individual predicted tacrolimus concentration of the fourth dosing occasion (MAXEVAL = 0, FOCE‐I) from 1–3 prior dosing occasions; and (ii) simulation‐based assessment (prediction‐corrected visual predictive check). Both assessments were stratified based on concomitant azole antifungal use. Results: Regardless of the number of prior dosing occasions (1–3) and concomitant azole antifungal use, all models demonstrated unacceptable individual predicted tacrolimus concentration of the fourth dosing occasion (n = 152). The prediction‐corrected visual predictive check graphics indicated that these models inadequately predicted observed tacrolimus concentrations. Conclusion: All models evaluated were unable to adequately describe tacrolimus pharmacokinetics in adult heart transplant recipients included in this study. Further work is required to describe tacrolimus pharmacokinetics for our heart transplant recipient cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
182. HEMO2life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study.
- Author
-
Le Meur, Yannick, Delpy, Eric, Renard, Felix, Hauet, Thierry, Badet, Lionel, Rerolle, Jean Philippe, Thierry, Antoine, Büchler, Matthias, Zal, Franck, and Barrou, Benoit
- Subjects
- *
KIDNEY physiology , *KIDNEYS , *LONGITUDINAL method , *COHORT analysis , *KIDNEY transplantation , *BASILIXIMAB - Abstract
Background: M101 is an extracellular hemoglobin isolated from a marine lugworm and is present in the medical device HEMO2life®. The clinical investigation OXYOP was a paired kidney analysis (n = 60) designed to evaluate the safety and performance of HEMO2life® used as an additive to preservation solution in renal transplantation. The secondary efficacy endpoints showed less delayed graft function (DGF) and better renal function in the HEMO2life® group but due to the study design cold ischemia time (CIT) was longer in the contralateral kidneys. Methods: An additional analysis was conducted including OXYOP patients and patients from the ASTRE database (n = 6584) to verify that the decrease in DGF rates observed in the HEMO2life® group may not be due solely to the shorter CIT but also to HEMO2life® performance. Kaplan–Meier estimate curves of cumulative probability of achieving a creatinine level below 250 µmol/L were generated and compared in both groups. A Cox model was used to test the effect of the explanatory variables (use of HEMO2life® and CIT). Finally, a bootstrap strategy was used to randomly select smaller samples of patients and test them for statistical comparison in the ASTRE database. Results: Kaplan–Meier estimate curves confirmed the existence of a relation between DGF and CIT and Cox analysis showed a benefit in the HEMO2life® group regardless of the associated CIT. Boostrap analysis confirmed these results. Conclusions: The present study suggested that the better recovery of renal function observed among kidneys preserved with HEMO2life® in the OXYOP study is a therapeutic benefit of this breakthrough innovative medical device. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
183. Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy.
- Author
-
Bemben, Nina M. and Berg, Melody L.
- Subjects
- *
DRUG therapy , *IMMUNOSUPPRESSIVE agents , *VACCINE effectiveness , *PRIMARY immunodeficiency diseases , *IMMUNOCOMPROMISED patients , *INFLUENZA , *BASILIXIMAB - Abstract
Inactivated vaccines are generally considered safe in immunocompromised patients but the ability of immunocompromised patients to generate an effective immune response to vaccines is uncertain. Although recent reviews have focused on the effects of vaccines in patients who are immunocompromised due to various disease states (primary immunodeficiency), the effects of immunosuppressive drug therapy (secondary immunodeficiency) has received relatively less attention. This review evaluates evidence regarding the efficacy of inactivated vaccines against influenza, COVID‐19, and other diseases in patients treated with immunosuppressive oncologic agents, immunosuppressants used for transplant recipients, and immunosuppressants used for autoimmune disorders. Although evidence is mixed for many immunosuppressive agents and vaccines, most studies have found an attenuated immune response to inactivated vaccines, with the majority of data indicate anti‐B‐cell antibodies have a more severe and prolonged negative effect on vaccine efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
184. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
- Author
-
Camacho-Bydume, Christine, Mauguen, Audrey, Rodriguez-Sanchez, M. Irene, Klein, Elizabeth, Kernan, Nancy A., Prockop, Susan, Boelens, Jaap Jan, Papanicolaou, Genovefa A., and Cancio, Maria
- Subjects
- *
STEM cell transplantation , *CYTOMEGALOVIRUS diseases , *HEMATOPOIETIC stem cells , *BASILIXIMAB , *OVERALL survival , *CHILD patients , *CYTOMEGALOVIRUSES - Abstract
Cytomegalovirus (CMV) reactivation is a significant complication following allogeneic hematopoietic stem cell transplant (HSCT) and affects upwards of 40% of pediatric HSCT patients. Pre-emptive therapy remains the only effective treatment strategy available for pediatric patients following CMV reactivation. Little is known about how the timing of induction treatment following CMV reactivation impacts outcomes in pediatric patients, especially following ex vivo T-cell-depleted (TCD) HSCT. The authors evaluated how the timing of induction treatment after CMV reactivation impacts overall survival (OS) and CMV disease in pediatric patients undergoing TCD HSCT at a single institution. The authors retrospectively analyzed patients treated on the pediatric service who received an initial ex vivo TCD HSCT at Memorial Sloan Kettering Cancer Center (MSKCC) from January 2010 to June 2018. CMV reactivation was defined as ≥1 CMV polymerase chain reaction >500 copies/mL in whole blood or >137 IU/mL in plasma within the first 180 days after allogeneic HSCT. To analyze the impact of the timing of induction treatment, the authors' primary study outcome was OS and secondary outcome was CMV disease. A total of 169 patients who underwent an initial allogeneic TCD HSCT on the pediatric service at MSKCC from January 2010 to June 2018 were included in the analysis. Thirty-seven (22%) patients reactivated CMV during the first 180 days following HSCT. Of those patients who reactivated CMV, CMV donor/recipient (D/R) serostatus was as follows: D+/R+ n = 28 (76%) and D–/R+ n = 9 (24%). There was no CMV reactivation observed among recipients who were CMV-seronegative irrespective of donor serostatus. In those patients who reactivated CMV, the median time from HSCT to CMV reactivation was 24 days (interquartile range, 20–31). Eleven patients ultimately developed CMV disease in addition to CMV viremia, whereas the remaining patients had only CMV viremia. The cumulative incidence of CMV reactivation at 60 days was 45.2% (95% confidence interval [CI], 32.8–57.5) in the D+/R+ subgroup and 31% (95% CI, 14.2–47.9) in the D–/R+ subgroup. For those patients who reactivated CMV, 30 (81%) received induction treatment with ganciclovir or foscarnet. To analyze the impact of the timing of induction treatment on clinical outcomes, the authors restricted the analysis to those patients who reactivated CMV and received induction treatment (n = 30). The timing of induction treatment was significantly associated with OS, with optimal timing of initiation within a week of CMV reactivation (P = 0.02). There was no significant impact on the timing of induction treatment and risk of CMV disease (P = 0.30). In ex vivo TCD HSCT in pediatric patients, early initiation of induction treatment after CMV reactivation is associated with improved OS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
185. High soluble HLA‐DQB2 levels in posttransplant serum are associated with kidney graft dysfunction.
- Author
-
Mine, Karina L, de Marco, Renato, Raimundo, Tamiris R.F., Ernesto, Julia V., Medina‐Pestana, José O., Tedesco‐Silva, Hélio, and Gerbase‐DeLima, Maria
- Subjects
- *
HLA histocompatibility antigens , *SINGLE nucleotide polymorphisms , *ENZYME-linked immunosorbent assay , *KIDNEYS , *GENETIC polymorphisms , *GLOMERULAR filtration rate , *BASILIXIMAB - Abstract
HLA‐DQB2 is a gene of limited polymorphism, with unknown function that presents at least two transcript variants: v1, which encodes the full‐length beta‐chain, and v2, which lacks exon 4 and could give rise to a soluble protein. We previously showed a strong correlation between high v2 expression in preimplantation biopsies (PIB) of kidneys from young (18‐ to 49‐year olds) but not from old, deceased donors and 1‐year posttransplant low (estimated glomerular filtration rate < 45 ml/min/1.73 m2) graft function (GF). In this study, we aimed to investigate the impact of posttransplant soluble HLA‐DQB2 (sDQB2) serum levels, v1 expression in PIB, and recipient HLA‐DQB2 rs7453920 A/G polymorphism on GF. sDQB2 was evaluated by enzyme‐linked immunosorbent assay in sera from 114 recipients, collected at least 1 year (median 2.1 years) after transplantation. Higher sDQB2 levels were observed in recipients of kidneys from young, but not from old, donors that had a ≥30% decline in GF within 1 year after blood collection for sDQB2 determination. Among the 15 recipients of kidneys from young donors with sDQB2 ≥ 1.52 ng/ml, 40% presented a ≥30% decline in GF, whereas this occurred in none of the 43 recipients with lower sDQB2 levels (p = 0.007; OR: 36.5). Expression of HLA‐DQB2 variant 1, measured by reverse transcription‐polymerase chain reaction (RT‐PCR) in 92 PIB from young or old donors, did not significantly differ between transplants with high or low 4‐year GF. HLA‐DQB2 rs7453920 single nucleotide polymorphism (SNP) frequencies did not significantly differ between recipients with low or high 4‐year GF. We conclude that HLA‐DQB2 variant 1 expression in PIB and recipient rs7453920 SNP polymorphism are not associated with graft outcome. On the other hand, the association, in transplants of kidneys from young donors, between high posttransplant serum sDQB2 levels and decline in GF is a very interesting finding that deserves a validation study in a larger cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
186. Topical calcineurin inhibitors as a double‐edged sword in rosacea: A systematic review.
- Author
-
Zhang, Hanlin, Yang, Leyan, Wang, Yuchen, Zhang, Dingyue, Tang, Keyun, Fang, Rouyu, and Sun, Qiuning
- Subjects
- *
ROSACEA , *CALCINEURIN , *PIMECROLIMUS , *TACROLIMUS , *CUTANEOUS manifestations of general diseases , *BASILIXIMAB - Abstract
Background: Rosacea is a chronic inflammatory disease mainly with skin or ocular manifestations. Topical calcineurin inhibitors, pimecrolimus and tacrolimus, can be used to treat rosacea. However, they can also induce rosacea‐like eruptions. Aims: This study systematically reviewed the double‐edged sword effects of pimecrolimus and tacrolimus on rosacea. Methods: Four databases were retrieved to search for articles on the effects of pimecrolimus and tacrolimus on rosacea, including Cochrane Library, Embase, PubMed, and Web of Science. Only English articles were included in the systematic review. Relevant data were collected, and the levels of evidence were evaluated. Results: 28 articles published between 2001 and 2016 were included. 11 articles were about pimecrolimus as the treatment of rosacea, 4 articles were about the pimecrolimus‐induced rosacea, 9 articles were about tacrolimus as the treatment of rosacea, and 4 articles were about tacrolimus‐induced rosacea. Participants for each study ranged from 1 to 200. Several types of outcome measurements were used for these publications. Conclusions: Both pimecrolimus and tacrolimus might have double‐edged sword effects on rosacea. Pimecrolimus and tacrolimus could be effective for rosacea. However, both of them could also induce rosacea. Larger, randomized, controlled studies on pimecrolimus and tacrolimus as the treatment of rosacea and studies on the mechanisms of pimecrolimus and tacrolimus in treating or inducing rosacea are needed. This systematic review emphasized the double‐edged sword role of topical calcineurin inhibitors in rosacea, which may pave the way for future research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
187. Outcomes in Live Renal Allograft Transplants with Different Modalities of Induction: A Hospital-Based Retrospective Study in Odisha.
- Author
-
Hota, Datteswar, Chakraborty, Sucharita, Dash, Kumar Avijeet, Kar, Chittaranjan, Rout, Shashi Bhusan, Acharya, Aruna, and Mahali, Debasish
- Subjects
THERAPEUTIC use of monoclonal antibodies ,MATHEMATICAL statistics ,HOMOGRAFTS ,BIOPSY ,GRAFT rejection ,PARAMETERS (Statistics) ,CONFIDENCE intervals ,STEROIDS ,ONE-way analysis of variance ,KIDNEY transplantation ,RETROSPECTIVE studies ,GRAFT survival ,ACQUISITION of data ,FISHER exact test ,COMPARATIVE studies ,MEDICAL records ,DESCRIPTIVE statistics ,CHI-squared test ,KAPLAN-Meier estimator ,GLOBULINS ,DATA analysis software ,ODDS ratio ,TACROLIMUS ,CREATININE - Abstract
Introduction: The immunosuppressant regimen after kidney transplantation typically includes initial induction therapy followed by a maintenance regimen. The induction therapy was introduced with the aim of reducing acute rejections. A retrospective study was conducted to compare the outcomes in patients with different modalities of induction. Materials and Methods: This is a hospital-based retrospective study where 148 patients who have undergone live renal allograft transplantation at SCB Medical College and Hospital from March 2012 to February 2019 were included in the study. All cases included were crossmatch negative, ABO-compatible live renal allograft transplantations. All patients received tacrolimus, mycophenolate sodium, and steroids. Induction therapy varied depending on immunological risk and changes in protocol over time. Basiliximab, anti-T-lymphocyte globulin (ATLG), and anti-thymocyte globulin (ATG) were given in 56, 21, and 21 patients, respectively, and no induction therapy in 50 patients. All patients with an acute rise in serum creatinine and without an obvious cause of graft dysfunction were subjected to renal biopsy. The incidence of acute rejection, patient survival, and graft survival was calculated from the follow-up records and compared among patients receiving different induction therapies. Results: In the high-risk category patients, 31%, 20%, and 18.2% of patients (P = 0.6) and in the low risk category, 37%, 27.3%, and 20% of patients (P = 0.6) had acute rejections in basiliximab, ATLG, and ATG group, respectively. The patient survival at 1 year was 79.3%, 70%, and 81.8% in high-risk group patients (P = 0.84) and 88.9%, 81.8%, and 80% in low-risk group patients (P = 0.88) in the basiliximab, ATLG, and ATG groups, respectively. The graft survival at 2 years was 96.6%, 90%, and 90.9% in high-risk group patients (P = 0.32) and 88.9%, 90.9%, and 90% in low-risk group patients (P = 0.65) in the basiliximab, ATLG, and ATG groups, respectively. Conclusion: In the low-risk group, the use of different modalities of induction does not have any advantage over no induction therapy in reducing the incidence of acute rejection, or improving patient and graft survival. In the high-risk group, all the induction therapies used lead to similar outcomes and none show any advantage over the other in terms of statistical significance. However, patients who received ATLG or ATG have an increased incidence of septicemia as compared to basiliximab and no induction group. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
188. Oxidative Stress and Ischemia/Reperfusion Injury in Kidney Transplantation: Focus on Ferroptosis, Mitophagy and New Antioxidants.
- Author
-
Granata, Simona, Votrico, Valentina, Spadaccino, Federica, Catalano, Valeria, Netti, Giuseppe Stefano, Ranieri, Elena, Stallone, Giovanni, and Zaza, Gianluigi
- Subjects
REPERFUSION injury ,KIDNEY transplantation ,OXIDATIVE stress ,KIDNEY injuries ,CELL death ,ISCHEMIA ,BASILIXIMAB ,AUTOPHAGY - Abstract
Although there has been technical and pharmacological progress in kidney transplant medicine, some patients may experience acute post-transplant complications. Among the mechanisms involved in these conditions, ischemia/reperfusion (I/R) injury may have a primary pathophysiological role since it is one of the leading causes of delayed graft function (DGF), a slow recovery of the renal function with the need for dialysis (generally during the first week after transplantation). DGF has a significant social and economic impact as it is associated with prolonged hospitalization and the development of severe complications (including acute rejection). During I/R injury, oxidative stress plays a major role activating several pathways including ferroptosis, an iron-driven cell death characterized by iron accumulation and excessive lipid peroxidation, and mitophagy, a selective degradation of damaged mitochondria by autophagy. Ferroptosis may contribute to the renal damage, while mitophagy can have a protective role by reducing the release of reactive oxygen species from dysfunctional mitochondria. Deep comprehension of both pathways may offer the possibility of identifying new early diagnostic noninvasive biomarkers of DGF and introducing new clinically employable pharmacological strategies. In this review we summarize all relevant knowledge in this field and discuss current antioxidant pharmacological strategies that could represent, in the next future, potential treatments for I/R injury. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
189. Intermittent Exposure of Hypercapnia Suppresses Allograft Rejection via Induction of Treg Differentiation and Inhibition of Neutrophil Accumulation.
- Author
-
Tzeng, Yuan-Sheng, Peng, Yi-Jen, Tang, Shih-En, Huang, Kun-Lun, Chu, Shi-Jye, Wu, Shu-Yu, and Cheng, Chia-Pi
- Subjects
GRAFT rejection ,REGULATORY T cells ,HYPERCAPNIA ,SKIN grafting ,T cells ,BASILIXIMAB - Abstract
Background: In the management of major burn wounds, allogeneic skin transplantation is a critical procedure to improve wound repair. Our previous works found that intermittent exposure to carbon dioxide leads to permissive hypercapnia (HCA) and prolongs skin allograft survival. However, the modulatory effects of HCA exposure on the immune system are not well understood. Objectives: Our purpose was to investigate how intermittent exposure to HCA can effectively reduce the immune reaction to allogeneic skin graft rejection. Methods: A fully major histocompatibility complex-incompatible skin transplant from BALB/c to C57BL/6 mice model was utilized. Immune cells from splenic and draining lymph nodes were analyzed by flow cytometry. Serum proinflammatory cytokines were analyzed by ELISA. Results: Serum levels of IFN-γ, IL-2, IL-6, and TNF-α were significantly decreased in the HCA group. Additionally, the percentage of CD8+ cells in draining lymph nodes was significantly lower in HCA than in the control group. Moreover, the generation rate of FoxP3+ regulatory T cells (Tregs) from spleen naïve CD4+ T cells was increased by intermittent exposure to carbon dioxide. The infiltrated neutrophils were also eliminated by HCA. Taken together, we concluded that intermittent hypercapnia exposure could effectively suppress skin rejection by stimulating Treg cell generation and suppressing immune reactions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
190. Researchers from University of Illinois Report New Studies and Findings in the Area of Chemicals and Chemistry (Clinical Outcomes of Intestinal Transplant Recipients Receiving Maintenance Basiliximab, Sublingual Tacrolimus and Prednisone: a...).
- Subjects
TACROLIMUS ,PREDNISONE ,RESEARCH personnel ,KIDNEY transplantation ,SUBLINGUAL drug administration ,BASILIXIMAB ,TREATMENT effectiveness - Abstract
Researchers from the University of Illinois have conducted a study on the clinical outcomes of intestinal transplant recipients who received a novel immunosuppression regimen. The study analyzed the data of five patients who underwent intestinal transplantation and were followed for at least one year post-transplant. The results showed that the combination of monthly basiliximab, sublingual tacrolimus, and prednisone was effective in maintaining immunosuppression and all patients were alive with functioning intestinal allografts at one year. However, the researchers suggest that further studies with a larger sample size and longer duration are needed to assess the safety and sustained benefits of this regimen. [Extracted from the article]
- Published
- 2024
191. Basiliximab: Lack of efficacy.
- Subjects
- *
NASAL cannula , *OXYGEN therapy , *LUNG transplantation , *BASILIXIMAB , *PATHOLOGY - Abstract
A 62-year-old man experienced lack of efficacy during treatment with basiliximab as an immunosuppressive treatment after undergoing a right lung transplant for COPD. The patient developed graft dysfunction and had extensive mucus plugging in the right lower lobe, which was resistant to treatment. Bronchoscopy confirmed a diagnosis of plastic bronchitis, and multiple procedures were performed to clear the airways. The patient was successfully extubated and discharged from the hospital on post-op day 21 while still requiring supplemental oxygen. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
192. Alliance Healthcare s.r.o. secures contract for Immunosuppressive agents - Medicinal preparations containing Sekukinumab 150mg and Basiliximab
- Subjects
Basiliximab ,Contract agreement ,News, opinion and commentary - Abstract
Czechia based Alliance Healthcare s.r.o. has secured contract from Fakultni nemocnice Hradec Kralove for Immunosuppressive agents - Medicinal preparations containing Sekukinumab 150mg and Basiliximab. The value of the contract is [...]
- Published
- 2023
193. Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
- Author
-
Masashi Furukawa, Ernest G. Chan, John P. Ryan, Eric J. Hyzny, Lauren M. Sacha, Jenalee N. Coster, Joseph M. Pilewski, Elizabeth A. Lendermon, Silpa D. Kilaru, John F. McDyer, and Pablo G. Sanchez
- Subjects
lung transplant ,induction immunosuppression therapy ,basiliximab ,alemtuzumab ,acute cellular rejection ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundInduction therapy is used in about 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guidelines for the use of induction therapy. At our institution, we have two induction strategies, basiliximab, and alemtuzumab. The goal of this manuscript is to share our experience and practice since this is an area of controversy.MethodsWe retrospectively reviewed 807 lung transplants performed at our institution between 2011 and 2020. Indications for the use of the basiliximab protocol were as follows: patients over the age of 70 years, history of cancer, hepatitis C virus or human immunodeficiency virus infection history, and cytomegalovirus or Epstein-Barr virus (donor positive/ recipient negative). In the absence of these clinical factors, the alemtuzumab protocol was used.Results453 patients underwent alemtuzumab induction and 354 patients underwent basiliximab. There were significant differences in delayed chest closure (24.7% alemtuzumab vs 31.4% basiliximab, p = 0.037), grade 3 primary graft dysfunction observed within 72 hours (19.9% alemtuzumab vs 29.9% basiliximab, p = 0.002), postoperative hepatic dysfunction (8.8% alemtuzumab vs 14.7% basiliximab, p = 0.009), acute cellular rejection in first year (39.1% alemtuzumab vs 53.4% basiliximab, p < 0.001). The overall survival rate of the patients with alemtuzumab induction was significantly higher than those of the patients with basiliximab induction (5 years survival rate: 64.1% alemtuzumab vs 52.3%, basiliximab, p < 0.001). Multivariate Cox regression analysis confirmed lower 5-year survival for basiliximab induction (HR = 1.41, p = 0.02), recipient cytomegalovirus positive (HR = 1.49, p = 0.01), postoperative hepatic dysfunction (HR = 2.20, p < 0.001), and acute kidney injury requiring renal replacement therapy (HR = 2.27, p < 0.001).ConclusionsIn this single center retrospective review, there was a significant difference in survival rates between induction strategies. This outcome may be attributable to differences in recipient characteristics between the groups. However, the Alemtuzumab group experienced less episodes of acute cellular rejection within the first year.
- Published
- 2022
- Full Text
- View/download PDF
194. Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients (CERTES02)
- Author
-
novartis
- Published
- 2018
195. Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
- Author
-
National Cancer Institute (NCI)
- Published
- 2018
196. Clinical outcomes of intestinal transplant recipients receiving maintenance basiliximab, sublingual tacrolimus and prednisone: A case series.
- Author
-
Di Cocco, Pierpaolo, Martinino, Alessandro, Bencini, Giulia, Christensen, Rachel, Valdepenas III, Benito, Petrochenkov, Egor, Akshelyan, Stepan, Almario-Alvarez, Jorge, Spaggiari, Mario, Tzvetanov, Ivo, and Benedetti, Enrico
- Subjects
- *
BASILIXIMAB , *TACROLIMUS , *PREDNISONE , *TREATMENT effectiveness , *ELECTRONIC health records - Abstract
Intestinal transplantation poses a unique challenge in the field of solid organ transplantation. The combination of tacrolimus and prednisone stands as the foundational cornerstone of maintenance immunosuppression in the field of intestinal transplantation. This case series aims to describe 1–year clinical outcomes of 5 intestinal transplant recipients who received a novel immunosuppression regimen consisting of monthly basiliximab, sublingual tacrolimus, and prednisone. A retrospective analysis of patients who underwent intestinal transplantation in our center between January 01, 2020, and January 31, 2022, was conducted. Each recipient was followed for at least 1-year post-transplant. Recipient baseline demographics, clinical characteristics, and follow-up data were obtained from the electronic health records. Data collection included recipient demographics (age, sex, race/ethnicity, BMI), cause of intestinal failure, immunological data, infectiology data and treatment information. A total of five patients underwent intestinal transplantation, of which two males (40 %) and three females (60 %), with a median age of 20.1 years (17.4–28.8). The median (IQR) tacrolimus trough by month 1 was 10.4 (8.4–13.2) ng/mL. Subsequently, the median (IQR) tacrolimus troughs at specified periods are as follows, respectively: month 3: 10.2 (8.2–13.2) ng/mL; month 6: 8.4 (7.6–9.6) ng/mL; and month 12: 8.8 (6.2–9.8) ng/mL. Three patients (60.0 %) had biopsy proven rejection, but all of them had resolution after the optimization of immunosuppression. All patients were alive and had a functioning intestinal allograft at 1-year. The combination of monthly basiliximab, sublingual tacrolimus, and prednisone is an effective novel maintenance immunosuppression in intestinal transplantation. A larger and more extended study duration would be necessary to thoroughly assess the safety and sustained benefits of the novel maintenance immunosuppression regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
197. (1400) - A Comparative Study Between Single vs Standard Two Doses of Basiliximab in Lung Transplantation.
- Author
-
Logan, A.T., Qureshi, M., Martin, M., Zerdo, H., and Patel, K.
- Subjects
- *
LUNG transplantation , *BASILIXIMAB , *COMPARATIVE studies - Published
- 2024
- Full Text
- View/download PDF
198. (1392) - Comparison of Basiliximab and Anti-Thymocyte Globulin as Induction Therapy for Simultaneous Heart-Kidney Transplantation in the Contemporary Era.
- Author
-
Huang, X., Carver, B., Choe, J., Salerno, D., Shertel, T., Colombo, P.C., Yuzefpolskaya, M., and Jennings, D.L.
- Subjects
- *
BASILIXIMAB , *GLOBULINS - Published
- 2024
- Full Text
- View/download PDF
199. (715) - The Influence of Basiliximab Induction Therapy on the Early Postoperative Outcomes / on Acute Cellular Rejection of Heart Transplant Recipients.
- Author
-
Nadziakiewicz, P. and Wajda-Pokrontka, M.
- Subjects
- *
GRAFT rejection , *HEART transplant recipients , *BASILIXIMAB , *KIDNEY transplantation , *TREATMENT effectiveness - Published
- 2024
- Full Text
- View/download PDF
200. (388) - Effect of Basiliximab versus Rabbit Anti-Thymocyte Globulin on Cardiac Allograft Vasculopathy Progression After Heart Transplantation.
- Author
-
Ródenas Alesina, E., Kugathasan, L., Foroutan, F., McDonald, M., Ross, H., and Alba, A.
- Subjects
- *
HEART transplantation , *BASILIXIMAB , *GLOBULINS , *HOMOGRAFTS , *VASCULAR diseases - Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.